AP NEWS

QIAGEN’s QuantiFERON-TB® Gold Plus Wins UN Migration Agency’s Tender

July 30, 2018

HILDEN, Germany, and GERMANTOWN, Md.--(BUSINESS WIRE)--Jul 30, 2018--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON-TB ® Gold Plus (QFT-Plus), the gold standard in accurate, cost-effective testing for latent tuberculosis (TB) infection, has been adopted by the International Organization for Migration (IOM) for use in screening migrants for the infection.

As the United Nations migration agency, IOM coordinates comprehensive healthcare for about 20 million migrants, refugees and asylum-seekers around the world. The IOM tender covers use of QFT-Plus in 16 countries in Africa, Asia and the Middle East facing public health challenges from TB as part of their 5-year Global Plan to End TB 2016-2020.

QIAGEN is collaborating with governments and international institutions, non-governmental organizations and commercial partners in fighting the global epidemic of tuberculosis. Experts around the world are increasingly recognizing that accurate, laboratory-based screening for latent TB infections – which can progress to active, contagious tuberculosis – is essential to effective TB control. So far in 2018, the World Health Organization (WHO) and U.S. Centers for Disease Control (CDC) all have endorsed latent TB screening with interferon-gamma release assays (IGRAs) such as QIAGEN’s fourth-generation QFT-Plus and third-generation QuantiFERON-TB ®  Gold (QFT). Furthermore, the International Panel Physicians Association (IPPA) has endorsed QFT-Plus specifically.

Please find the full press release here

###

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005548/en/

CONTACT: Investor Relations

John Gilardi

+49 2103 29 11711

or

Dr. Sarah Fakih

+49 2103 29 11457

e-mail:ir@QIAGEN.com

or

Public Relations

Dr. Thomas Theuringer

+49 2103 29 11826

or

Robert Reitze

+49 2103 29 11676

e-mail:pr@QIAGEN.com

KEYWORD: UNITED STATES EUROPE NORTH AMERICA MARYLAND GERMANY

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: QIAGEN N.V.

Copyright Business Wire 2018.

PUB: 07/30/2018 04:07 PM/DISC: 07/30/2018 04:07 PM

http://www.businesswire.com/news/home/20180730005548/en

AP RADIO
Update hourly